Public Companies
Red Light Holland: Substantial Revenue Increase And Streamlined Operational Performance In Fiscal 2023
Red Light Holland Corp. (OTC: TRUFF), the functional mushroom company with a psychedelic twist, reported audited annual financial statements for fiscal…
Red Light Holland Corp. (OTC: TRUFF), the functional mushroom company with a psychedelic twist, reported audited annual financial statements for fiscal 2023. It was record year of growth—including 5-digit percentage growth in certain divisions.
For the year, Red Light Holland produced record revenue of $3.95 million, which was an 69.8% increase over the $2.33 million generated in 2022. The rise in ‘wholesale mushroom sales’ was by far the greatest contributor to this gain, growing an astounding 10,998% year-over-year, while ‘mushroom grow kit sales’ increased 218.86%, in part to the acquisition of Minichamp (see below). Core ‘wholesale product sales’ remained stable, with a small increase in fiscal 2023 revenues.
Wholesale mushroom sales grew 10,998% year-over-year in fiscal 2023, Source: Red Light Holland Consolidated Financial Statements for the years ended March 31, 2023 and 2022
Interestingly, the higher revenue occurred despite a twenty-nine percent (28.96%) decrease in operating expenses. If we exclude share-based compensation, the revenue bump still came amid a 2.85% decrease in remaining OpEx. This would generally be considered a positive trend towards operational efficiency.
Operating expenses refer to the costs incurred in running the day-to-day business ...
Full story available on Benzinga.com
psychedelic mushroom otc red light holland-
Psilocybin1 week ago
California advances bill for psychedelics centers
-
Psilocybin5 days ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
Psychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics5 days ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics5 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics5 days ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Law & Regulation5 days ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics6 days ago
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research